. Author manuscript; available in PMC: 2013 Feb 14.

Published in final edited form as: Cancer Cell. 2012 Feb 14;21(2):240–252. doi: 10.1016/j.ccr.2011.12.027

Table 3.

Tumor formation by primary MPNST cells in immunocompetent C57BL/Ka mice and immunocompromised NOD/SCID ILR2γ^null mice

Tumor	Recipient mice	Injected cell dose			Tumorigenic cells (%)	95% CI
Tumor	Recipient mice	100	10	5	Tumorigenic cells (%)	95% CI
Nf1^+/−;Ink4a/Arf^−/− (35)	C57Bl6 (BA)	5/5	4/5		16	5.4–48
Nf1^+/−;Ink4a/Arf^−/− (35)	NOD/SCID IL2Rγ^null	5/5	4/5		16	5.4–48
Nf1^+/−;Ink4a/Arf^−/− (40)	C57Bl6 (BA)			4/7	17	6.2–46
Nf1^+/−;Ink4a/Arf^−/− (40)	NOD/SCID IL2Rγ^null			5/8	20	7.9–49
Nf1^+/−;p53^+/− (7)	C57Bl6 (BA)	5/5	3/8		5.0	1.8–13
Nf1^+/−;p53^+/− (7)	NOD/SCID IL2Rγ^null	4/5	3/7		2.5	1.0–6.5
Nf1^+/−;p53^+/− (28)	C57Bl6 (BA)	3/5	1/8		1.0	0.4–2.8
Nf1^+/−;p53^+/− (28)	NOD/SCID IL2Rγ^null	2/5	1/8		0.6	0.2–2.1